<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: <z:hpo ids='HP_0005549'>Congenital neutropenia</z:hpo> is a group of <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> that involve <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0002719'>susceptibility to infections</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>These <z:hpo ids='HP_0001875'>neutropenias</z:hpo> may be isolated or associated with immunologic defects or extra-hematopoietic manifestations </plain></SENT>
<SENT sid="2" pm="."><plain>Complications may occur as <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e>, but also less frequently as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, the transcription factor GATA2 has been identified as a new predisposing gene for familial <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study, we describe the initial identification by exome sequencing of a GATA2 R396Q mutation in a family with a history of <z:hpo ids='HP_0011010'>chronic</z:hpo> mild <z:hpo ids='HP_0001875'>neutropenia</z:hpo> evolving to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The subsequent analysis of the French Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> Registry allowed the identification of 6 additional pedigrees and 10 patients with 6 different and not previously reportedGATA2 mutations (R204X, E224X, R330X, A372T, M388V, and a complete deletion of the GATA2 locus) </plain></SENT>
<SENT sid="6" pm="."><plain>The frequent evolution to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in these patients reveals the importance of screening GATA2 in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> associated with <z:mp ids='MP_0000223'>monocytopenia</z:mp> because of the frequent hematopoietic transformation, variable clinical expression at <z:hpo ids='HP_0003674'>onset</z:hpo>, and the need for aggressive therapy in patients with poor clinical outcome </plain></SENT>
<SENT sid="7" pm="."><plain>KEY POINTS: Mutations of key transcription factor in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>